Price
$7.46
Decreased by -2.99%
Dollar Volume
2.92 M
ADR%
5.82
Earnings Report Date (estimate)
Nov 9, 22 (-0.28)
Market Cap.
460.87 M
Shares Float
44.10 M
Shares Outstanding
61.78 M
Beta
1.62
Price / Earnings
-4.84
BPR
838.10
20D Range
6.35 7.88
50D Range
5.92 10.02
200D Range
1.05 10.02
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.33
Increased by +13.16%
-0.25
Decreased by -32.00%
Aug 9, 22 -1.07
Decreased by -224.24%
-0.41
Decreased by -160.98%
May 9, 22 -0.45
Decreased by -95.65%
-0.43
Decreased by -4.65%
Mar 17, 22 -0.38
Decreased by -100.00%
-0.41
Increased by +7.32%
Nov 8, 21 -0.38
Decreased by -90.00%
-0.38
Aug 9, 21 -0.33
Decreased by -167.35%
-0.31
Decreased by -6.45%
May 10, 21 -0.23
Decreased by -1.05 K%
-0.32
Increased by +28.13%
Mar 9, 21 -0.19
Decreased by -171.43%
-0.27
Increased by +29.63%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-20.15 M
Increased by +8.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-63.44 M
Decreased by -224.01%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-26.42 M
Decreased by -96.53%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-22.30 M
Decreased by -97.74%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-22.00 M
Decreased by -88.00%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
-19.58 M
Decreased by -163.42%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by -100.00%
-13.45 M
Decreased by -1.45 K%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by -100.00%
-11.28 M
Decreased by -311.76%
Decreased by -50.50 T%
Decreased by -202.71 T%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.